Drug Shows Activity In Men With Advanced Prostate Cancer, Memorial Sloan-Kettering Cancer Center Study

ScienceDaily (Apr. 13, 2009) — A new multi-center study shows that an experimental drug lowers prostate specific antigen (PSA) levels – a marker for tumor growth – in men with advanced prostate cancer for whom traditional treatment options have failed. The study, led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC), is published in Science Express, the online version of the journal Science.